Exozymes Inc (EXOZ) Stock Price, Quote & News

Company Profile

eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 626 415 1488

Website: www.exozymes.com

Address:

750 Royal Oaks Drive, Suite 106, Monrovia, United States

B2iDigital May. 9 at 12:29 AM

eXoZymes (Nasdaq: $EXOZ ) CEO Michael Heltzen frames the company’s platform as a new form of chemistry with applications across nutraceuticals and pharmaceuticals. eXoZymes Inc. (NASDAQ: EXOZ) CEO Michael Heltzen appeared on The Upside to discuss the company’s cell-free biomanufacturing platform, its focus on NCT, and the broader opportunity to apply AI-engineered enzymes outside the cell. Watch the clip here:https://youtube.com/shorts/KHARx1GscpQ?feature=share eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1. Asked about eXoZymes’ growth potential, Heltzen says the company is “here to make it really, really large” and describes the platform as “a new form of chemistry.” In the full interview, Heltzen discusses NCT, a naturally occurring molecule found in black pepper, and explains how eXoZymes’ platform is designed to produce compounds at scale. He also describes the company’s dual-track opportunity: an over-the-counter nutraceutical path for natural NCT and a pharmaceutical path for more potent analogs. eXoZymes is a Monrovia, California-based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to transform sustainable feedstocks into high-value compounds. The company is currently focused on products including NCT, non-intoxicating cannabinoids, and other applications where its platform may offer advantages in speed, purity, and scalability. Learn more at https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $DNLI, $TWST, $DNA, $ARKG

1 · Reply

Slack_Capital May. 7 at 6:32 AM

$EXOZ Another interview with Michael Heltzen - CEO of eXoZymes https://t.co/5kH1BbvdNW

0 · Reply

Slack_Capital Apr. 28 at 11:39 PM

$EXOZ delivers on everything under the surface!!

0 · Reply

B2iDigital Apr. 21 at 5:40 PM

eXoZymes (Nasdaq: $EXOZ ) CEO Michael Heltzen was featured on Session 20 of the GeneCoda podcast Executive Insights for Life Sciences Innovators, in an episode titled “AI-enabled cell-free biomanufacturing and the future of enzyme engineering,” streamed live on YouTube on April 17. eXoZymes is a B2i Digital Featured Company. See their full profile at https://b2idigital.com/exozymes-1. In the conversation, Heltzen discusses the company’s thesis that producing complex molecules outside living cells can enable greater control, scalability, and speed compared to traditional biologic manufacturing. The discussion also covers how AI is helping identify and optimize enzyme pathways, the strategic considerations involved in building a platform company in today’s capital environment, what differentiates cell-free systems from established synthetic biology approaches, and where cell-free biomanufacturing could create commercial impact across nutraceutical, pharmaceutical, and industrial markets. Watch or listen here: https://exozymes.com/blog/podcast-genecoda-2026 Separately, eXoZymes and Cayman Chemical were featured in a Springwise case study on how the two companies are rethinking chemical manufacturing. The piece focuses on eXoZymes’ work bringing enzyme pathways from biology into the world of chemistry, with Cayman Chemical helping to scale the approach. CCO Damien Perriman is featured in the article. See the eXoZymes summary: https://exozymes.com/blog/springwise-2026 eXoZymes is a Los Angeles, California-based biotechnology company that has developed a biomanufacturing platform offering the tools and insights to design, engineer, control, and optimize nature’s own natural processes to produce highly valuable natural products via a commercially scalable, sustainable, and abundant alternative: exozymes. eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Lasse H. Görlitz, VP of Communications; and Amy Lunzer, Chief of Staff. Learn more about eXoZymes Inc. at https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor and learn about other B2i Digital Featured Companies at https://b2idigital.com/featured-companies. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $DNLI, $TWST, $DNA, $ARKG

1 · Reply

SuperGreenToday Apr. 21 at 3:44 PM

$EXOZ

0 · Reply

Veshy Apr. 15 at 8:57 AM

$EXOZ When is the financing expected to close?

1 · Reply

Slack_Capital Apr. 15 at 4:13 AM

$EXOZ Come join the eXoZymes Investors Discord group I have set up!

1 · Reply

KOWALSK1 Apr. 14 at 8:40 AM

$EXOZ another 56% call

0 · Reply

eXoZymes Apr. 13 at 6:02 PM

$EXOZ Biotech Bulls & Breakthroughs podcast: The Future of Biomanufacturing with Michael Heltzen In this episode of Biotech Bulls & Breakthroughs, John Gagliano of BioPharmCatalyst sits down with Michael Heltzen, CEO of eXoZymes, to discuss the revolutionary move toward cell-free biomanufacturing. Discover how eXoZymes is using AI to bypass the limitations of living cells, engineering "super-enzymes" through brute-force evolution, and bringing high-purity natural compounds like NCT to the mass market. https://exozymes.com/blog/biotech-bulls-breakthroughs-2026

0 · Reply

focafoca99 Apr. 10 at 6:10 PM

$EXOZ used a podcast appearance to outline the NCTx spinout strategy and the commercial path it sees for cell-free biomanufacturing.

0 · Reply

eXoZymes announces graduation from Shell GameChanger Accelerator

May 7, 2026, 9:05 AM EDT - 1 day ago

eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program

Apr 10, 2026, 9:10 AM EDT - 4 weeks ago

eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast

Mar 31, 2026, 5:30 PM EDT - 5 weeks ago

eXoZymes Earnings Call Transcript: Q4 2025

Mar 31, 2026, 4:20 PM EDT - 5 weeks ago

eXoZymes Provides Fourth Quarter and Full Year 2025 Update

Mar 25, 2026, 4:10 PM EDT - 6 weeks ago

eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026

2026-03-18T13:15:28.000Z - 7 weeks ago

eXoZymes announces validation milestone for its biomanufacturing platform

Mar 18, 2026, 9:10 AM EDT - 7 weeks ago

Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability

Mar 12, 2026, 4:15 PM EDT - 2 months ago

eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium

Feb 10, 2026, 4:20 PM EST - 3 months ago

With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation

Jan 29, 2026, 7:45 PM EST - 3 months ago

eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run

2026-01-16T20:55:43.000Z - 4 months ago

eXoZymes files $50M mixed securities shelf

Dec 11, 2025, 4:10 PM EST - 5 months ago

eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion

2025-11-19T15:40:17.000Z - 6 months ago

eXoZymes Inc trading resumes

2025-11-19T15:35:09.000Z - 6 months ago

eXoZymes Inc trading halted, volatility trading pause

2025-11-18T16:35:49.000Z - 6 months ago

eXoZymes Inc trading resumes

2025-11-18T16:30:20.000Z - 6 months ago

eXoZymes Inc trading halted, volatility trading pause

Nov 13, 2025, 5:00 PM EST - 6 months ago

eXoZymes Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 6 months ago

eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today

Nov 13, 2025, 4:15 PM EST - 6 months ago

eXoZymes Announces Cell-Free Biomanufacturing Pioneer, Tyler Korman, As CSO & Amy Lunzer as Chief of Staff

Nov 10, 2025, 5:00 PM EST - 6 months ago

eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM EST

Oct 30, 2025, 4:10 PM EDT - 6 months ago

CEO of eXoZymes on 'AI in Life Sciences' panel at the Beryl Elites' Investment Conference

Oct 29, 2025, 5:40 PM EDT - 6 months ago

CEO of eXoZymes to Present at Spartan Capital Securities' Second Annual Investor Conference

2025-10-24T15:35:10.000Z - 7 months ago

eXoZymes Inc trading resumes

2025-10-24T15:30:20.000Z - 7 months ago

eXoZymes Inc trading halted, volatility trading pause

Oct 23, 2025, 4:50 PM EDT - 7 months ago

CEO of eXoZymes to Present at ThinkEquity's Annual Investor Conference

Sep 30, 2025, 4:10 PM EDT - 7 months ago

Driving the Cell-Free Revolution: eXoZymes Leaders Join BioMADE Leadership & Technical Committees

Aug 12, 2025, 5:00 PM EDT - 9 months ago

eXoZymes Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:50 PM EDT - 9 months ago

eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today

Aug 7, 2025, 6:35 PM EDT - 9 months ago

eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST

2025-07-29T12:31:33.000Z - 10 months ago

eXoZymes achieves four grams of NCT with over 99% purity

Jul 29, 2025, 7:57 AM EDT - 10 months ago

eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity

Jul 22, 2025, 4:10 PM EDT - 10 months ago

eXoZymes Biomanufacturing Breakthrough: From Concept to Gram-Scale NCT in Only 5 Months

2025-06-26T20:30:34.000Z - 11 months ago

eXoZymes announces role in $9.2M Meta-PURE initiative

Jun 26, 2025, 4:10 PM EDT - 11 months ago

eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing

May 16, 2025, 9:25 AM EDT - 1 year ago

eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast

May 12, 2025, 5:00 PM EDT - 1 year ago

eXoZymes Earnings Call Transcript: Q1 2025

May 12, 2025, 4:10 PM EDT - 1 year ago

eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today

May 7, 2025, 5:20 PM EDT - 1 year ago

eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST

May 6, 2025, 4:10 PM EDT - 1 year ago

eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health

Apr 21, 2025, 4:10 PM EDT - 1 year ago

Bringing clarity and precision to the cell-free space by introducing exozymes

Apr 10, 2025, 4:30 PM EDT - 1 year ago

BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant

Apr 2, 2025, 4:30 PM EDT - 1 year ago

eXoZymes Earnings Call Transcript: Q4 2024

2025-04-02T20:20:30.000Z - 1 year ago

eXoZymes appoints Damien Perriman chief commercial officer

Apr 2, 2025, 4:10 PM EDT - 1 year ago

eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO

Apr 2, 2025, 4:05 PM EDT - 1 year ago

eXoZymes Provides Fourth Quarter and Full Year 2024 Update

Mar 26, 2025, 5:00 PM EDT - 1 year ago

eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025

2025-03-17T17:45:05.000Z - 1 year ago

eXoZymes Inc trading resumes

2025-03-17T17:35:35.000Z - 1 year ago

eXoZymes Inc trading halted, volatility trading pause

2025-02-21T21:10:27.000Z - 1 year ago

eXoZymes president, chairman Hayat transitions out of roles

MDBH

Feb 21, 2025, 4:05 PM EST - 1 year ago

eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc.

2025-02-19T14:40:31.000Z - 1 year ago

eXoZymes Inc trading resumes

2025-02-19T14:35:46.000Z - 1 year ago

eXoZymes Inc trading halted, volatility trading pause

B2iDigital May. 9 at 12:29 AM

1 · Reply

Slack_Capital May. 7 at 6:32 AM

$EXOZ Another interview with Michael Heltzen - CEO of eXoZymes https://t.co/5kH1BbvdNW

0 · Reply

Slack_Capital Apr. 28 at 11:39 PM

$EXOZ delivers on everything under the surface!!

0 · Reply

B2iDigital Apr. 21 at 5:40 PM

1 · Reply

SuperGreenToday Apr. 21 at 3:44 PM

$EXOZ

0 · Reply

Veshy Apr. 15 at 8:57 AM

$EXOZ When is the financing expected to close?

1 · Reply

Slack_Capital Apr. 15 at 4:13 AM

$EXOZ Come join the eXoZymes Investors Discord group I have set up!

1 · Reply

KOWALSK1 Apr. 14 at 8:40 AM

$EXOZ another 56% call

0 · Reply

eXoZymes Apr. 13 at 6:02 PM

0 · Reply

focafoca99 Apr. 10 at 6:10 PM

$EXOZ used a podcast appearance to outline the NCTx spinout strategy and the commercial path it sees for cell-free biomanufacturing.

0 · Reply

LewisDaKat Apr. 10 at 6:00 PM

$EXOZ eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast https://marketwirenews.com/stock/exoz/news/exozymes-cco-damien-perriman-outlines-nctx-strategy--8021656043696277.html?utm_source=stocktwits

0 · Reply

B2iDigital Apr. 10 at 5:12 PM

eXoZymes (Nasdaq: $EXOZ ) announced an Open Lab Event at its facilities in Los Angeles on Wednesday, April 15, inviting current and prospective investors to hear a new investor-focused presentation from CEO Michael Heltzen, followed by a Q&A session and a founder-guided tour of the company’s labs. Two sessions are available: 10:00–11:30 AM and 1:30–3:00 PM. Space is limited. Sign up here: https://exozymes.com/open-lab-event eXoZymes is a B2i Digital Featured Company. See their full profile at https://b2idigital.com/exozymes-1. Separately, CCO Damien Perriman was featured on the latest episode of the Grow Everything podcast, where he discussed the launch of NCTx as a dedicated commercialization vehicle for NCT and the company’s approach to taking high-value molecules from development into the market. Perriman also discussed the recent third-party validation work with Cayman Chemical, where eXoZymes’ NCT production process was independently transferred and scaled 100-fold by Cayman Chemical, achieving approximately 99% conversion and 99.6% purity. “eXoZymes is building a disciplined model for bridging invention and market delivery. We remain focused on creating better ways to make important molecules, while vehicles like NCTx are designed to take those opportunities into the market with speed and purpose. When our process performs successfully in someone else’s hands at scale, it reinforces that cell-free biomanufacturing can be a practical commercial platform.” Watch the full episode: https://youtu.be/eDsyoZzwOJM?si=1iW2rcP3uCnPC0rq eXoZymes is a Los Angeles, California-based biotechnology company that has developed a biomanufacturing platform offering the tools and insights to design, engineer, control, and optimize nature’s own natural processes to produce highly valuable natural products via a commercially scalable, sustainable, and abundant alternative: exozymes. eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Lasse H. Görlitz, VP of Communications; and Amy Lunzer, Chief of Staff. Learn more about eXoZymes Inc. at https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor and learn about other B2i Digital Featured Companies at https://b2idigital.com/featured-companies. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in https://b2idigital.com/disclaimer. $DNLI, $TWST, $DNA, $ARKG

1 · Reply

B2iDigital Apr. 9 at 9:11 PM

In a recent article, eXoZymes (Nasdaq: $EXOZ ) was featured in The Village Voice for its work on NCT (N-trans-Caffeoyltyramine), a naturally occurring molecule at the center of a growing scientific conversation about metabolic health beyond GLP-1 weight-loss drugs. eXoZymes is a B2i Digital Featured Company. See their full profile at https://b2idigital.com/exozymes-1. eXoZymes has developed cell-free biomanufacturing methods capable of producing high-purity NCT at scale, turning a molecule once found only in trace amounts in peppercorns (roughly 0.0014 percent concentration) into one that can now be explored in depth. The article places that capability in the context of a broader shift in metabolic health research, where scientists are looking past appetite suppression toward approaches that address how the body burns energy at the cellular level. With over 1.4 billion people worldwide affected by obesity, diabetes, and metabolic dysfunction, the interest is growing. Preclinical research published in Nature Cell Death & Disease showed a roughly 30 percent reduction in weight gain in mouse models on a high-fat diet receiving NCT, with no change in food intake. While further studies are required before conclusions about human health can be drawn, the Village Voice piece places eXoZymes squarely at the forefront of the ongoing effort to produce the NCT molecule at scale. Read the complete article: https://www.villagevoice.com/the-metabolic-engine-how-scientists-are-exploring-a-new-path-beyond-glp-1-weight-loss-drugs/ eXoZymes is a Los Angeles, California-based biotechnology company pioneering cell-free biomanufacturing through AI-engineered enzymes that transform sustainable feedstock into nutraceuticals, medicines, and essential chemicals. The company’s proprietary exozyme platform offers a scalable, eco-friendly alternative to traditional petrochemical processes, with technology validated through publications in Nature Communications and Nature Chemical Biology. Recently demonstrating gram-scale production of NCT with over 99% purity in just five months, eXoZymes focuses on high-value products including active pharmaceutical ingredients, nutraceuticals, and sustainable aviation fuel. eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Lasse H. Görlitz, VP of Communications; and Amy Lunzer, Chief of Staff. Learn more about eXoZymes Inc. at https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor and learn about other B2i Digital Featured Companies at https://b2idigital.com/featured-companies. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $DNLI, $TWST, $DNA, $ARKG

1 · Reply

Slack_Capital Apr. 8 at 7:32 PM

@eXoZymes is a value generation flywheel, launching multiple high-value biotech verticals, one spin-out at a time NCT and Cannabinoids alone represent a $200B TAM and each new vertical stacks permanent, compounding value onto $EXOZ

1 · Reply

KOWALSK1 Apr. 8 at 9:34 AM

$EXOZ

0 · Reply

B2iDigital Apr. 7 at 5:42 PM

eXoZymes Inc. (Nasdaq: $EXOZ ) is pleased to participate in the Second Annual Centri Capital Conference, taking place Tuesday, April 14, 2026, at Nasdaq ($NDAQ ) MarketSite in New York City. The Centri Capital Conference is a B2i Digital Featured Conference. See more details at: https://b2idigital.com/centri-capital-conference-2026 eXoZymes Inc. (Nasdaq: $EXOZ ) is a biotechnology company that has developed a new way to produce chemicals without using living cells. The company's technology, called "exozymes," combines enzymes (proteins that speed up chemical reactions) with artificial intelligence to create a manufacturing platform that transforms biomass into chemicals, medicines, and fuels. Unlike traditional synthetic biology that relies on living cells, eXoZymes' cell-free approach operates more like industrial chemistry, avoiding the common problems that prevent biological manufacturing from reaching commercial scale. Building on a successful inaugural year, the Centri Capital Conference returns as a premier one-day event bringing together 500+ institutional investors, industry leaders, and executives from over 50 participating companies across healthcare, life sciences, technology, AI, digital assets, fintech, and other high-growth sectors. The full-day program features company presentations, fireside chats, curated one-on-one investor meetings, and a networking reception. B2i Digital is working closely with the Centri Business Consulting team, including Michael Aiello, Amanda Zeigler, Gerald Wik, Stephan Parico, Christopher Mora, Jaime Krug, Adam Batchelor, David Lawlor, Nikki Frazier, and Dale Jones to enhance each presenter's reach through B2i Digital's network of 1.5M+ investors. The Centri Capital Conference is an invite-only event. For more information and to request registration, visit: https://www.meetmax.com/sched/event_130523/conference_register.html?attendee_role_id=CENTRI_INVESTOR Learn more about eXoZymes Inc. at https://b2idigital.com/exozymes-1?hsLang=en. Content is for informational purposes only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.

1 · Reply

B2iDigital Apr. 1 at 1:21 PM

eXoZymes Inc. (NASDAQ: $EXOZ) provided its fourth quarter and full year 2025 operational update, with management hosting a conference call after the market closed on March 31, 2026. eXoZymes is a B2i Digital Featured Company. See their full profile at https://b2idigital.com/exozymes-1. During 2025, eXoZymes shifted from a broad partnership search to focus on advancing high-value product programs, e.g. NCT. The company’s approach, supported by selective spin-outs, joint ventures, and licensing, is designed to build more mature and commercially focused assets and capture a greater share of value creation and long-term upside. The company continued to validate its cell-free biomanufacturing platform throughout the year, progressing from idea to pilot-scale while delivering strong conversion, high purity, and process control. Following IPO execution and validation milestones, the company is preparing for its next phase of financing while maintaining a capital-efficient operating model. An S-3 was filed in January 2026 to enable engagement with prospective investors, alongside ongoing roadshow discussions ahead of the company’s next financing round. CEO Michael Heltzen states, “We’ve moved beyond our ‘big idea’ potential and into execution - building differentiated assets and capabilities in a capital-efficient way that we believe sets us apart. We expect to see further value generating inflection points as programs like NCT and our cannabinoid initiatives continue to advance through commercialization milestones.” Read the full press release here: https://exozymes.com/blog/4q-2025-investorcall eXoZymes is a Los Angeles, California-based biotechnology company that has developed a biomanufacturing platform offering the tools and insights to design, engineer, control, and optimize nature’s own natural processes to produce highly valuable natural products via a commercially scalable, sustainable, and abundant alternative: exozymes. eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Lasse Görlitz, VP of Communications; and Amy Lunzer, Chief of Staff. To learn more about eXoZymes Inc., visit https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.

1 · Reply

Veshy Mar. 25 at 11:46 AM

$EXOZ How is the company doing financially? Is there a fundraiser planned in the near future?

1 · Reply

KOWALSK1 Mar. 25 at 11:21 AM

$EXOZ Exozymes inc ✅️ BUY ZONE 7.25 to 7.08 ✋️ RISK BELOW 6.37 🎯 PT. 7.50 7.78 7.97 8.10 8.37 + UP Follow for more

0 · Reply

OfficialStocktwitsUser Mar. 24 at 7:53 PM

$EXOZ RSI: 54.34, MACD: -0.6176 Vol: 0.61, MA20: 7.57, MA50: 9.29 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Slack_Capital Mar. 19 at 3:56 AM

$EXOZ A must watch! External validation of eXoZymes platform https://www.youtube.com/watch?v=LumC3bTYICA&t=192s

0 · Reply

B2iDigital Mar. 18 at 8:12 PM

eXoZymes (Nasdaq: $EXOZ) has announced a third-party validation milestone for its cell-free biomanufacturing platform: independent partner Cayman Chemical successfully ran eXoZymes’ technology at pilot scale, delivering results consistent with, and in some cases exceeding, earlier internal runs. eXoZymes is a B2i Digital Featured Company. See their full profile at https://b2idigital.com/exozymes-1. Using eXoZymes’ tech transfer package, Cayman Chemical scaled the process from a one-liter setup to a 100-liter pilot run, operating the reaction, downstream processing, and analysis independently. Despite encountering real-world conditions such as pH variation and precipitation, factors that often cause enzyme-based processes to fail, the reaction performed reliably throughout, producing more than 500 grams of pharma-grade N-trans-caffeoyltyramine (NCT) at 99.6% purity and achieving 99% conversion of feedstock to end product. Patrick Westcott, Director of Catalog Chemistry Production at Cayman Chemical, commented: “During the experiment, from the first sample that we took the analysis showed over a 99% conversion rate. There was some concern because I thought that that maybe was a little bit too high. So, we decided to take a second sample to see if it maintained a similar conversion rate. And we were a little surprised to find out that we actually did achieve this 99% conversion in our first 100-fold scale up of their process. That was very much an aha moment for us!” eXoZymes CCO Damien Perriman added: “This pilot run is an important validation of our cell-free platform, demonstrating that it performs reliably at scale and delivers strong results in the hands of an external partner. The fact that this project reached pilot scale in less than a year underscores our ability to move R&D at a disruptive pace - and just as importantly - it meaningfully reduces platform execution risk by showing that our technology can be transferred and operated successfully beyond our own labs. With more than 500 grams of pharma-grade NCT now available from this run, we are actively engaging partners interested in evaluation, formulation development, and potential commercialization.” Read the full press release here: https://exozymes.com/blog/cayman-validation eXoZymes is a Monrovia, California-based biotechnology company pioneering cell-free biomanufacturing through AI-engineered enzymes that transform sustainable feedstock into nutraceuticals, medicines, and essential chemicals. eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Dr. Zachary Karl, VP of Business Development; Lasse H. Görlitz, VP of Communications; and Amy Lunzer, Chief of Staff. To learn more about eXoZymes Inc., visit https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.

1 · Reply

Market Cap	84.79M
Revenue (ttm)	0.00
Net Income (ttm)	-9.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	4,000
Avg Vol	4,868
Day's Range	N/A - N/A
Shares Out	8.48M
Stochastic %K	12%
Beta	2.85
Analysts	Strong Buy
Price Target	N/A